Patents by Inventor Rustum Boyce

Rustum Boyce has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130017196
    Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 17, 2013
    Inventors: Weibo Wang, Paul A. Barsanti, Yia Xia, Rustum Boyce, Sabina Pecchi, Nathan Brammeier, Megan C. Phillips, Kris Mendenhall, Kelly Wayman, Liana Marie Lagnition, Ryan Constantine, Hong Yang, Elizabeth Mieuli, Savithri Ramurthy, Elisa Jazan, Anu Sharma, Rama Jain, Sharadha Subramanian, Paul A. Renhowe, Kenneth W. Bair, David Duhl, Annette Walter, Tinya Abrams, Kay Huh, Eric Martin, Mark Knapp, Vincent P. Le
  • Patent number: 8318791
    Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: November 27, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Weibo Wang, Paul A. Barsanti, Yia Xia, Rustum Boyce, Sabina Pecchi, Nathan Brammeier, Megan C. Phillips, Kris Mendenhall, Kelly Wayman, Liana Marie Lagniton, Ryan Constantine, Hong Yang, Elizabeth Mieuli, Savithri Ramurthy, Elisa Jazan, Anu Sharma, Rama Jain, Sharadha Subramanian, Paul A. Renhowe, Kenneth W. Bair, David Duhl, Annette Walter, Tinya Abrams, Kay Huh, Eric Martin, Mark Knapp, Vincent P. Le
  • Publication number: 20120189623
    Abstract: The present invention relates to new substituted imidazole compounds have the following Formula (I) and to the pharmaceutically acceptable salts, esters, or prodrugs thereof, to compositions of the compounds together with pharmaceutically acceptable carriers, and to uses of the compounds:
    Type: Application
    Filed: April 3, 2012
    Publication date: July 26, 2012
    Inventors: Rustum Boyce, Eric Martin, Weibo Wang, Hong Yang, Paul A. Barsanti
  • Publication number: 20110003791
    Abstract: The present invention relates to new substituted imidazole compounds have the following Formula (I) and to the pharmaceutically acceptable salts, esters, or prodrugs thereof, to compositions of the compounds together with pharmaceutically acceptable carriers, and to uses of the compounds:
    Type: Application
    Filed: September 15, 2010
    Publication date: January 6, 2011
    Inventors: Rustum Boyce, Eric Martin, Weibo Wang, Hong Yang, Paul A. Barsanti
  • Patent number: 7820646
    Abstract: The present invention relates to new substituted imidazole compounds have the following Formula (I) and to the pharmaceutically acceptable salts, esters, or prodrugs thereof, to compositions of the compounds together with pharmaceutically acceptable carriers, and to uses of the compounds:
    Type: Grant
    Filed: January 3, 2008
    Date of Patent: October 26, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Rustum Boyce, Eric Martin, Weibo Wang, Hong Yang, Paul A. Barsanti
  • Patent number: 7626040
    Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses of the compounds.
    Type: Grant
    Filed: August 9, 2006
    Date of Patent: December 1, 2009
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Paul A. Barsanti, Yi Xia, Weibo Wang, Kris G. Mendenhall, Liana M. Lagniton, Savithri Ramurthy, Megan C. Phillips, Sharadha Subramanian, Rustum Boyce, Nathan M. Brammeier, Ryan Constantine, David Duhl, Annette O. Walter, Tinya J. Abrams, Paul A. Renhowe
  • Publication number: 20090258016
    Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Application
    Filed: June 5, 2009
    Publication date: October 15, 2009
    Inventors: Weibo Wang, Paul A. Barsanti, Yia Xia, Rustum Boyce, Sabina Pecchi, Nathan Brammeier, Megan C. Phillips, Kris Mendenhall, Kelly Wayman, Liana Marie Lagniton, Ryan Constantine, Hong Yang, Elizabeth Mieuli, Savithri Ramurthy, Elisa Jazan, Anu Sharma, Rama Jain, Sharadha Subramanian, Paul A. Renhowe, Kenneth W. Bair, David Duhl, Annette Walter, Tinya Abrams, Kay Huh, Eric Martin, Mark Knapp, Vincent P. Le
  • Patent number: 7576221
    Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Grant
    Filed: June 20, 2005
    Date of Patent: August 18, 2009
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Weibo Wang, Paul A. Barsanti, Yia Xia, Rustum Boyce, Sabina Pecchi, Nathan Brammeier, Megan C. Phillips, Kris Mendenhall, Kelly Wayman, Liana Marie Lagniton, Ryan Constantine, Hong Yang, Elizabeth Mieuli, Savithri Ramurthy, Elisa Jazan, Anu Sharma, Rama Jain, Sharadha Subramanian, Paul A. Renhowe, Kenneth W. Bair, David Duhl, Annette Walter, Tinya Abrams, Kay Huh, Eric Martin, Mark Knapp, Vincent P. Le
  • Patent number: 7456183
    Abstract: Compounds having the general structure I are provided. X and Y are independently selected from the group consisting of CH2, N, NR9, C?O, C?S, S?O, SO2, S, O, (CR6R7)n, C(?O)—(CR6R7)n, and C(?S)—(CR6R7)n, where n is 1, 2, or 3. W is selected from the group consisting of (formula I) and L is selected from the group consisting of N, O, S?O, SO2, C(O), NC(O), NC(S), OC(O), OC(S), C(NR10), C(NOR10), and a covalent bond. Z1, Z2, and Z3 are independently selected from the group consisting of substituted carbon and nitrogen. Compounds of formula I are agonists of the melanocortin-4 receptor (“MC-4r2) and therefore may have useful properties for controlling diseases related to MC-4r action in humans, such as obesity and type II diabetes.
    Type: Grant
    Filed: April 8, 2002
    Date of Patent: November 25, 2008
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Daniel Chu, Rustum Boyce, David Duhl, Bryan Chang
  • Publication number: 20080207589
    Abstract: The present invention relates to new substituted imidazole compounds have the following Formula (I) and to the pharmaceutically acceptable salts, esters, or prodrugs thereof, to compositions of the compounds together with pharmaceutically acceptable carriers, and to uses of the compounds:
    Type: Application
    Filed: January 3, 2008
    Publication date: August 28, 2008
    Inventors: Rustum Boyce, Eric Martin, Weibo Wang, Hong Yang, Paul A. Barsanti
  • Patent number: 7189727
    Abstract: Compounds having the general structure III are provided: where D is N or C; W is selected from Z1, Z2, and Z3 are independently selected from CR8 and N; and the other variables have the values described herein. Compounds of formula III have useful properties for controlling diseases related to MC4-R action in humans including obesity and type II diabetes.
    Type: Grant
    Filed: April 5, 2004
    Date of Patent: March 13, 2007
    Assignee: Chiron Corporation
    Inventors: Rustum Boyce, David Duhl
  • Publication number: 20070037853
    Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses of the compounds.
    Type: Application
    Filed: August 9, 2006
    Publication date: February 15, 2007
    Inventors: Paul Barsanti, Yi Xia, Weibo Wang, Kris Mendenhall, Liana Lagniton, Savithri Ramurthy, Megan Phillips, Sharadha Subramanian, Rustum Boyce, Nathan Brammeier, Ryan Constantine, David Duhl, Annette Walter, Tinya Abrams, Paul Renhowe
  • Publication number: 20060235019
    Abstract: A variety of low molecular weight, guanidino-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases. The compounds have the structure of Formulas (IA), (IB), or (IC): where the values of the variable are defined herein.
    Type: Application
    Filed: May 23, 2003
    Publication date: October 19, 2006
    Inventors: Rustum Boyce, Natalia Aurrecoechea, Daniel Chu, Aaron Smith
  • Publication number: 20060089369
    Abstract: New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.
    Type: Application
    Filed: September 6, 2005
    Publication date: April 27, 2006
    Applicant: Chiron Corporation
    Inventors: John Nuss, Stephen Harrison, David Ring, Rustum Boyce, Kirk Johnson, Keith Pfister, Savithri Ramurthy, Lynn Seely, Allan Wagman, Manoj Desai, Barry Levine
  • Publication number: 20060084687
    Abstract: The present invention relates to new indole and benzimidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Application
    Filed: October 14, 2005
    Publication date: April 20, 2006
    Inventors: Rustum Boyce, Hongyan Guo, Kris Mendenhall, Annette Walter, Weibo Wang, Yia Xia
  • Publication number: 20060030573
    Abstract: A variety of low molecular weight, guanidino-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases. The compounds have the structure IA, IB, or IC where the values of the variable are defined herein.
    Type: Application
    Filed: October 11, 2005
    Publication date: February 9, 2006
    Inventors: Rustum Boyce, Natalia Aurrecoechea, Daniel Chu, Aaron Smith, Bryan Chang
  • Publication number: 20060009472
    Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Application
    Filed: June 20, 2005
    Publication date: January 12, 2006
    Inventors: Weibo Wang, Paul Barsanti, Yi Xia, Rustum Boyce, Sabina Pecchi, Nathan Brammeier, Megan Phillips, Kris Mendenhall, Kelly Wayman, Liana Lagniton, Ryan Constantine, Hong Yang, Elizabeth Mieuli, Savithri Ramurthy, Elisa Jazan, Anu Sharma, Rama Jain, Sharadha Subramanian, Paul Renhowe, Kenneth Bair, David Duhl, Annette Walter, Tinya Abrams, Kay Huh, Eric Martin, Mark Knapp, Vincent Le
  • Patent number: 6960582
    Abstract: Compounds having the general structure II are provided: A is selected from the group consisting of C or CH and X and Y are independently selected from the group consisting of CH2, N, C?O, C?S, (CR6R7)n, S?O, SO2, O, NR9, S, C(?O)—(CR6R7)n, and C(?S)—(CR6R7)n where n is 1, 2, or 3. W is selected from the group consisting of and Z1, Z2, and Z3 are independently selected from the group consisting of substituted carbon and nitrogen. L is selected from the group consisting of N, O, S, S?O, SO2, C(O), NC(O), NC(S), OC(O), OC(S), C(NR10), C(NOR10), and a covalent bond. Compounds of formula II are agonists of the melanocortin-4 receptor (“MC4-R”) and therefore may have useful properties for controlling diseases related to MC4-R action in humans, such as obesity and type II diabetes.
    Type: Grant
    Filed: April 30, 2003
    Date of Patent: November 1, 2005
    Assignee: Chiron Corporation
    Inventors: Rustum Boyce, David Duhl
  • Publication number: 20050192297
    Abstract: A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the formula IA and IB.
    Type: Application
    Filed: November 19, 2004
    Publication date: September 1, 2005
    Inventors: Rustum Boyce, Jason Speake, James Phillips
  • Publication number: 20050124652
    Abstract: A variety of small, guanidino group-containing molecules capable of acting as MC4-R agonists are provided. The compounds have various structures provided herein. The compounds are useful in treating MC4-R mediated diseases and may be formulated into pharmaceutical formulations and compositions.
    Type: Application
    Filed: February 3, 2003
    Publication date: June 9, 2005
    Inventors: Rustum Boyce, Daniel Chu